WEGOVY FLEXTOUCH 2.4MG PRE-FILLED PEN + 4MM NEEDLES

Description

Wegovy FlexTouch 2.4mg Solution for Injection in Pre-Filled Pen + 4mm Needles (4)

Adults

Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of

• ≥30 kg/m2 (obesity), or
• ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity.

Adolescents (≥12 years)

Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with

• obesity* and
• body weight above 60 kg.

Treatment with Wegovy should be discontinued and re-evaluated if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.

Contains 3.2 mg/mL of semaglutide*. Each dose contains 2.4mg of semaglutide in 0.75mL solution. One pre-filled pen contains 9.6 mg (four doses) of semaglutide in 3 mL solution.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.